These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Bouabdallah K; Ribrag V; Terriou L; Soria JC; Delarue R Curr Opin Oncol; 2013 Mar; 25 Suppl 2():S1-12. PubMed ID: 23388840 [TBL] [Abstract][Full Text] [Related]
16. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Coiffier B; Ribrag V Leuk Lymphoma; 2009 Dec; 50(12):1916-30. PubMed ID: 19757306 [TBL] [Abstract][Full Text] [Related]
17. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. Armstrong AJ; George DJ; Halabi S J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270 [TBL] [Abstract][Full Text] [Related]
18. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series. Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140 [TBL] [Abstract][Full Text] [Related]